Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma. NICE technology appraisal guidance 865
National Institute for Health and Care Excellence (NICE)
Record ID 32018011906
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta865
Year Published:
2023
URL for published report:
https://www.nice.org.uk/guidance/ta865
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Esophageal Neoplasms
- Nivolumab
- Esophageal Squamous Cell Carcinoma
- Antineoplastic Combined Chemotherapy Protocols
- Antibodies, Monoclonal
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.